Immunogenicity and Safety of AdCLD-CoV19-1 OMI As a Booster: a COVID-19 Preventive Vaccine in Healthy Volunteers

计划入组 4,000 人 · 首次发布于 2023 年 8 月 15 日

Safety and Immunogenicity of AdCLD-CoV19-1 OMI as a Booster: A SARS-CoV-2 (COVID-19) Preventive Vaccine

计划入组 320 人 · 首次发布于 2022 年 10 月 12 日

Safety and Immunogenicity of COVID-19 Vaccine, AdCLD-CoV19-1

计划入组 200 人

AdCLD-CoV19-1

AdCLD-Cov19

OMI-DG1

NHI-1

United States

Xi'an No.1 Hospital

China

ALPHA-1 FOUNDATION, INC.

United States

Cellid Completes Phase 3 Dosing of Omicron-Targeted COVID-19 Vaccine

Powerful Medical's AI-Driven ECG Model for STEMI Detection Receives FDA Breakthrough Designation

Gilead's Lenacapavir Shows Promise in HIV Prevention, While GLP-1s Studied for Type 1 Diabetes